Revance Therapeutics, Inc.

NasdaqGM:RVNC 株式レポート

時価総額:US$398.6m

Revance Therapeutics マネジメント

マネジメント 基準チェック /24

Revance Therapeuticsの CEO はMark Foleyで、 Oct2019年に任命され、 の在任期間は 5.08年です。 の年間総報酬は$ 10.07Mで、 7.2%給与と92.8%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の1.06%を直接所有しており、その価値は$ 4.21M 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と5.4年です。

主要情報

Mark Foley

最高経営責任者

US$10.1m

報酬総額

CEO給与比率7.2%
CEO在任期間5.1yrs
CEOの所有権1.1%
経営陣の平均在職期間5.3yrs
取締役会の平均在任期間5.4yrs

経営陣の近況

Recent updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Sep 26

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28
Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10
Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10
Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14
Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Apr 17
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Jan 02
Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia

Oct 20

Revance climbs 14% as FDA approves facial injectable for frown lines

Sep 08

Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems

Aug 24

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Aug 04
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

CEO報酬分析

Revance Therapeutics の収益と比較して、Mark Foley の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$303m

Jun 30 2024n/an/a

-US$304m

Mar 31 2024n/an/a

-US$325m

Dec 31 2023US$10mUS$720k

-US$324m

Sep 30 2023n/an/a

-US$292m

Jun 30 2023n/an/a

-US$337m

Mar 31 2023n/an/a

-US$341m

Dec 31 2022US$7mUS$673k

-US$356m

Sep 30 2022n/an/a

-US$274m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$274m

Dec 31 2021US$7mUS$660k

-US$281m

Sep 30 2021n/an/a

-US$297m

Jun 30 2021n/an/a

-US$303m

Mar 31 2021n/an/a

-US$292m

Dec 31 2020US$9mUS$650k

-US$282m

Sep 30 2020n/an/a

-US$249m

Jun 30 2020n/an/a

-US$209m

Mar 31 2020n/an/a

-US$186m

Dec 31 2019US$18mUS$190k

-US$159m

Sep 30 2019n/an/a

-US$155m

Jun 30 2019n/an/a

-US$146m

Mar 31 2019n/an/a

-US$143m

Dec 31 2018US$243kn/a

-US$143m

Sep 30 2018n/an/a

-US$138m

Jun 30 2018n/an/a

-US$136m

Mar 31 2018n/an/a

-US$128m

Dec 31 2017US$338kn/a

-US$121m

報酬と市場: Markの 総報酬 ($USD 10.07M ) は、 US市場 ($USD 2.24M ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Mark Foley (59 yo)

5.1yrs

在職期間

US$10,068,915

報酬

Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Mark Foley
CEO & Director5.1yrsUS$10.07m1.06%
$ 4.2m
Tobin Schilke
CFO & Principal Accounting Officer6yrsUS$3.97m0.092%
$ 368.6k
Dwight Moxie
Chief Legal Officer & General Counsel4.8yrsUS$3.53m0.046%
$ 181.7k
Jessica Serra
Head of Investor Relations & ESGno dataデータなしデータなし
Jeanie Herbert
Senior Director of Investor Relations & Corporate Communications7.9yrsデータなしデータなし
Taryn Conway
Vice President of Marketing5.6yrsデータなしデータなし
Amie Krause
Chief People Officer1.7yrsデータなしデータなし
Conor Gallagher
Head of Medical Affairs & Aesthetics6.5yrsデータなしデータなし
David Hollander
Chief Medical Officer of Global Therapeutics Franchise Lead1.8yrsデータなし0.0057%
$ 22.9k
Erica Jordan
Chief Commercial Officerno dataデータなし0.11%
$ 436.5k

5.3yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: RVNCの経営陣は経験豊富で経験豊富です(平均在職期間は5.3年)。


取締役

名称ポジション在職期間報酬所有権
Mark Foley
CEO & Director7.2yrsUS$10.07m1.06%
$ 4.2m
Angus Russell
Independent Chairman10.7yrsUS$346.03k0.049%
$ 195.7k
Jill Beraud
Independent Director5.4yrsUS$317.53k0.042%
$ 165.7k
Julian Gangolli
Independent Director8.3yrsUS$305.03k0.043%
$ 171.4k
Vladimir Coric
Independent Director1.7yrsUS$421.49k0.020%
$ 79.0k
Olivia Ware
Independent Director3.7yrsUS$295.03k0.030%
$ 120.3k
Carey Kolaja
Independent Director3.7yrsUS$304.18k0.030%
$ 119.9k
Christian Nolet
Independent Director5.3yrsUS$315.03k0.042%
$ 165.7k

5.4yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: RVNCの 取締役会経験豊富 であると考えられます ( 5.4年の平均在任期間)。